SCHEMBL20072234

SCHEMBL20072234

COc1ccccc1CCOC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.59
MTNR1B P49286 1/20 0.59
ALOX5 P09917 1/20 0.56
TAAR1 Q96RJ0 1/20 0.53
CNR1 P21554 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
AOC3 Q16853 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM1 P11229 1/20 0.47
NR3C2 P08235 1/20 0.47
HPGD P15428 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA5A P35218 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27993616 0.86 PTGS2 (0.51) MTNR1AMTNR1BALOX5HPGD
SCHEMBL16244485 0.85 TAAR1 (0.56) MTNR1AMTNR1BALOX5TAAR1AOC3
SCHEMBL7185351 0.84 MTNR1A (0.54) MTNR1AMTNR1BALOX5TAAR1SIGMAR1
SCHEMBL28298040 0.83 L3MBTL1 (0.56)
SCHEMBL20072351 0.83 TAAR1 (0.53) MTNR1AMTNR1BALOX5TAAR1SIGMAR1
SCHEMBL1030014 0.82 IDO1 (0.56) MTNR1AMTNR1BTAAR1HPGD
SCHEMBL23803511 0.82 ALOX5 (0.52) MTNR1AMTNR1BALOX5TAAR1SIGMAR1
SCHEMBL23925503 0.82 MTNR1A (0.55) MTNR1AMTNR1BALOX5TAAR1SIGMAR1
SCHEMBL23841132 0.82 ALOX5 (0.52) MTNR1AMTNR1BALOX5TAAR1SIGMAR1
SCHEMBL28324732 0.82 LMNA (0.56) MTNR1AMTNR1BALOX5TAAR1CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11162104-B2 SCN9A antisense pain killer OLIPASS CORPORATION (KR) 2021-11-02 US disclosed
US-20190345202-A1 ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2019-11-14 US disclosed
US-20190337987-A1 EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES OLIPASS CORPORATION (KR) 2019-11-07 US disclosed
WO-2018069764-A1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345202-A1 ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES AR, NR5A1, NR5A2 MTNR1A 170/4885MTNR1B 352/4885ALOX5 725/4885
US-20190337987-A1 EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES PTBP1, RBM17, UPF1 MTNR1A 3239/4885MTNR1B 2388/4885ALOX5 1842/4885
US-11162104-B2 SCN9A antisense pain killer SCN9A, SCN7A, SCN8A MTNR1A 1889/4885MTNR1B 1256/4885ALOX5 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.